Cholangitis

Liscure Biosciences has launched a Phase 2 clinical trial to test whether its experimental probiotic LB-P8 can improve gut health and reduce liver inflammation…

Up to three years of treatment with Gilead Sciences‘ Livdelzi (seladelpar) results in sustained reductions in itching and biomarkers of liver injury in adults…

The most recent assessment of liver stiffness best predicts the future risk of liver disease progression among adults with primary biliary cholangitis (PBC), regardless…

Oct. 29 is Global PSC Awareness Day, and advocates around the world are joining forces to shine a light on primary sclerosing cholangitis (PSC)…

AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to…

Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name Lyvdelzi — as a second-line…

Women with primary biliary cholangitis (PBC) may be at increased risk of having disease flares in the months following childbirth, according to a small…

A family whose experience with biliary atresia led to an effort to help others navigate the challenges of pediatric liver disease is among those being…

Aramchol, a small molecule in the Galmed Pharmaceuticals pipeline, prevented and reversed inflammation and scarring (fibrosis) of the bile ducts in mouse models of…

The American Liver Foundation (ALF) is launching a first-of-its kind national database, called the ALF Living Donor Network, to connect people willing to…